REVIEW Klotho: a humeral mediator in CSF and plasma that influences longevity and susceptibility to multiple complex disorders, including depression

Translational Psychiatry

Volumn 6, Issue 8, 2016, Pages

  Pavlatou, M G ^a   Remaley, A T ^b   Gold, P W ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; CALCIUM; INSULIN; KLOTHO PROTEIN; PHOSPHATE; SOMATOMEDIN; VITAMIN D;

AGING; ANIMAL; ATHEROSCLEROSIS; BIPOLAR DISORDER; CALCINOSIS; CARDIOVASCULAR DISEASE; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEPRESSION; GENETICS; GLYCOSYLATION; HUMAN; LONGEVITY; MAJOR DEPRESSION; METABOLISM; MOUSE; OSTEOPOROSIS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

AGING; ANIMALS; ATHEROSCLEROSIS; BIPOLAR DISORDER; CALCINOSIS; CALCIUM; CARDIOVASCULAR DISEASES; COGNITIVE DYSFUNCTION; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; GLUCURONIDASE; GLYCOSYLATION; HUMANS; INSULIN; LONGEVITY; MICE; OSTEOPOROSIS; OXIDATIVE STRESS; PHOSPHATES; SIGNAL TRANSDUCTION; SOMATOMEDINS; STROKE; VITAMIN D;

EID: 84991500234     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2016.135     Document Type: Review

References (110)

1. Arking DE, Krebsova A, Macek M Sr, Macek M Jr, Arking A, Mian IS et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA 2002; 99: 856–861.
2. Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003; 72: 1154–1161.
3. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45–51.
4. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 1998; 242: 626–630.
5. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104: 19796–19801.
6. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 2004; 565: 143–147.
7. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124–136.
8. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005; 280: 38029–38034.
9. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H et al. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 2008; 27: 7094–7105.
10. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829–1833.
11. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005; 310: 490–493.
12. Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317: 803–806.
13. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, Suga T et al. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998; 248: 324–329.
14. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A et al. alpha-Klotho as a regulator of calcium homeostasis. Science 2007; 316: 1615–1618.
15. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770–774.
16. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429–435.
17. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125–131.
18. Nabeshima Y, Imura H. alpha-Klotho: a regulator that integrates calcium homeostasis. Am J Nephrol 2008; 28: 455–464.
19. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y et al. Estab-lishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 2010; 398: 513–518.
20. Ohata Y, Arahori H, Namba N, Kitaoka T, Hirai H, Wada K et al. Circulating levels of soluble alpha-Klotho are markedly elevated in human umbilical cord blood. J Clin Endocrinol Metab 2011; 96: E943–E947.
21. Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med 1995; 1: 703–705.
22. Roth EF Jr., Friedman M, Ueda Y, Tellez I, Trager W, Nagel RL. Sickling rates of human AS red cells infected in vitro with Plasmodium falciparum malaria. Science 1978; 202: 650–652.
23. Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro OM, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA 2008; 105: 9805–9810.
24. Ohtsubo K, Takamatsu S, Minowa MT, Yoshida A, Takeuchi M, Marth JD. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell 2005; 123: 1307–1321.
25. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006; 126: 855–867.
26. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004; 306: 120–124.
27. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586–600.
28. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62: 427–433.
29. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1: 634–646.
30. Selman C, Lingard S, Choudhury AI, Batterham RL, Claret M, Clements M et al. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J 2008; 22: 807–818.
31. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003; 299: 1346–1351.
32. Unger RH. Klotho-induced insulin resistance: a blessing in disguise? Nat Med 2006; 12: 56–57.
33. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J 2003; 17: 50–52.
34. Shiozaki M, Yoshimura K, Shibata M, Koike M, Matsuura N, Uchiyama Y et al. Morphological and biochemical signs of age-related neurodegenerative changes in klotho mutant mice. Neuroscience 2008; 152: 924–941.
35. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C et al. Plasma Klotho and cardiovascular disease in adults. J Am Geriatr Soc 2011; 59: 1596–1601.
36. Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res 2005; 96: 412–418.
37. Majumdar V, Nagaraja D, Christopher R. Association of the functional KL-VS variant of Klotho gene with early-onset ischemic stroke. Biochem Biophys Res Commun 2010; 403: 412–416.
38. Oguro R, Kamide K, Kokubo Y, Shimaoka I, Congrains A, Horio T et al. Association of carotid atherosclerosis with genetic polymorphisms of the klotho gene in patients with hypertension. Geriatr Gerontol Int 2010; 10: 311–318.
39. Shimoyama Y, Nishio K, Hamajima N, Niwa T. KLOTHO gene polymorphisms G-395 A and C1818T are associated with lipid and glucose metabolism, bone mineral density and systolic blood pressure in Japanese healthy subjects. Clin Chim Acta 2009; 406: 134–138.
40. Imamura A, Okumura K, Ogawa Y, Murakami R, Torigoe M, Numaguchi Y et al. Klotho gene polymorphism may be a genetic risk factor for atherosclerotic coronary artery disease but not for vasospastic angina in Japanese. Clin Chim Acta 2006; 371: 66–70.
41. Majumdar V, Jose D, Christopher R. Influence of Klotho genotypes on plasma NO (x) levels in South Indian population. Thromb Res 2011; 128: 251–255.
42. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27–III32.
43. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4.
44. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126.
45. Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010; 9: 830–834.
46. Saito Y, Nakamura T, Ohyama Y, Suzuki T, Iida A, Shiraki-Iida T et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 2000; 276: 767–772.
47. Rakugi H, Matsukawa N, Ishikawa K, Yang J, Imai M, Ikushima M et al. Anti-oxidative effect of Klotho on endothelial cells through cAMP activation. Endocrine 2007; 31: 82–87.
48. Kusaba T, Okigaki M, Matui A, Murakami M, Ishikawa K, Kimura T et al. Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci USA 2010; 107: 19308–19313.
49. Maekawa Y, Ohishi M, Ikushima M, Yamamoto K, Yasuda O, Oguro R et al. Klotho protein diminishes endothelial apoptosis and senescence via a mitogen-activated kinase pathway. Geriatr Gerontol Int 2011; 11: 510–516.
50. Maekawa Y, Ishikawa K, Yasuda O, Oguro R, Hanasaki H, Kida I et al. Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endo-thelium and attenuates NF-kappaB activation. Endocrine 2009; 35: 341–346.
51. Ogata N, Matsumura Y, Shiraki M, Kawano K, Koshizuka Y, Hosoi T et al. Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women. Bone 2002; 31: 37–42.
52. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteo-porosis. J Bone Miner Res 1996; 11: 1043–1051.
53. Marie PJ, Kassem M. Extrinsic mechanisms involved in age-related defective bone formation. J Clin Endocrinol Metab 2011; 96: 600–609.
54. Bilezikian JP, Marcus R, Levine MA. Physiological aspects of the parathyroid. In: Bilezikian JP, Marcus R, Levine MA (eds). The Parathyroids: Basic and Clinical Concepts. Academic Press: New York, NY, USA, 2003, pp 167–291.
55. Wilson JD, Foster DW, Kronenberg HM, Larsen PR. Hormones and disorders of mineral metabolism. In: Bringhurst FR, Demay M, Kronenberg HM (eds). Williams Text-book of Endocrinology. Saunders: Philadelphia, PA, USA, 2003, pp 1303–1371.
56. Nabeshima Y. The discovery of alpha-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis. Cell Mol Life Sci 2008; 65: 3218–3230.
57. Tsuruoka S, Nishiki K, Ioka T, Ando H, Saito Y, Kurabayashi M et al. Defect in parathyroid-hormone-induced luminal calcium absorption in connecting tubules of Klotho mice. Nephrol Dial Transplant 2006; 21: 2762–2767.
58. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81: 239–297.
59. Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H et al. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA 1998; 95: 1387–1391.
60. Kim E, Barrett SMB, Boitano Scott, Heddwen Brooks. Hormonal control of calcium and phosphate metabolism and the physiology of bone. In: Lange/McGraw-Hill (ed). Ganong's Review of Medical Physiology. McGraw-Hill Medical: New York, NY, USA, 2010, pp 363–375.
61. Hoenderop JG, van Leeuwen JP, van der Eerden BC, Kersten FF, van der Kemp AW, Merillat AM et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003; 112: 1906–1914.
62. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabo-lism. Endocrinol Metab Clin North Am 2010; 39: 243–253, table of contents.
63. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120–6123.
64. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561–568.
65. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG et al. Homozygous ablation of fibroblast growth factor-23 results in hyperpho-sphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23: 421–432.
66. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17: 2393–2403.
67. Yamashita T, Nifuji A, Furuya K, Nabeshima Y, Noda M. Elongation of the epi-physeal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging. J Endocrinol 1998; 159: 1–8.
68. Yamashita T, Yoshitake H, Tsuji K, Kawaguchi N, Nabeshima Y, Noda M. Retar-dation in bone resorption after bone marrow ablation in klotho mutant mice. Endocrinology 2000; 141: 438–445.
69. Kashimada K, Yamashita T, Tsuji K, Nifuji A, Mizutani S, Nabeshima Y et al. Defects in growth and bone metabolism in klotho mutant mice are resistant to GH treatment. J Endocrinol 2002; 174: 403–410.
70. Teitelbaum SL. Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc Natl Acad Sci USA 2004; 101: 16711–16712.
71. Almeida M, Han L, Ambrogini E, Bartell SM, Manolagas SC. Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/ p66shc signaling cascade: counter regulation by estrogens or androgens. Mol Endocrinol 2010; 24: 2030–2037.
72. Liu F, Wu S, Ren H, Gu J. Klotho suppresses RIG-I-mediated senescence-associated inflammation. Nat Cell Biol 2011; 13: 254–262.
73. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004; 29: 91–99.
74. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24: 3438–3450.
75. Farrow EG, Davis SI, Summers LJ, White KE. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009; 20: 955–960.
76. Hu MC, Shi M, Zhang J, Quinones H, Kuro-o M, Moe OW. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010; 78: 1240–1251.
77. Aizawa H, Saito Y, Nakamura T, Inoue M, Imanari T, Ohyama Y et al. Down-regulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 1998; 249: 865–871.
78. Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T, Sasaki T et al. Ameli-oration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA 2007; 104: 2331–2336.
79. Zhao Y, Banerjee S, Dey N, LeJeune WS, Sarkar PS, Brobey R et al. Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes 2011; 60: 1907–1916.
80. Sugiura H, Yoshida T, Mitobe M, Yoshida S, Shiohira S, Nitta K et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant 2010; 25: 60–68.
81. Albaaj F, Hutchison A. Hyperphosphataemia in renal failure: causes, consequences and current management. Drugs 2003; 63: 577–596.
82. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12: 387–403.
83. Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18: 2996–3003.
84. de Francisco AM, Ellis HA, Owen JP, Cassidy MJ, Farndon JR, Ward MK et al. Parathyroidectomy in chronic renal failure. Q J Med 1985; 55: 289–315.
85. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38: 931–936.
86. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453–1464.
87. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.
88. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. Circulation 2003; 108: 2154–2169.
89. Levin NW, Hoenich NA. Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens 2001; 10: 563–568.
90. Salusky IB, Goodman WG. Managing phosphate retention: is a change necessary? Nephrol Dial Transplant 2000; 15: 1738–1742.
91. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002; 39: 838–843.
92. Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M. Inde-pendent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 1999; 104: 229–237.
93. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG et al. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid func-tion. Kidney Int 1993; 44: 860–866.
94. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333: 166–174.
95. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001; 280: 1015–1020.
96. Lee J, Jeong DJ, Kim J, Lee S, Park JH, Chang B et al. The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer 2010; 9: 109.
97. Pan J, Zhong J, Gan LH, Chen SJ, Jin HC, Wang X et al. Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. Tumour Biol 2011; 32: 729–735.
98. Wang L, Wang X, Jie P, Lu H, Zhang S, Lin X et al. Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res 2011; 1: 111–119.
99. Chen B, Wang X, Zhao W, Wu J. Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res 2010; 29: 99.
100. Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R et al. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene 2010; 29: 26–33.
101. Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C et al. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res 2011; 17: 4254–4266.
102. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148–1159.
103. Perez-Plasencia C, Duenas-Gonzalez A, Alatorre-Tavera B. Second hit in cervical carcinogenesis process: involvement of wnt/beta catenin pathway. Int Arch Med 2008; 1: 10.
104. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C et al. Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci 2011; 66: 794–800.
105. Scheiner-Bobis G. The sodium pump. Its molecular properties and mechanics of ion transport. Eur J Biochem 2002; 269: 2424–2433.
106. Anamizu Y, Kawaguchi H, Seichi A, Yamaguchi S, Kawakami E, Kanda N et al. Klotho insufficiency causes decrease of ribosomal RNA gene transcription activity, cytoplasmic RNA and rough ER in the spinal anterior horn cells. Acta Neuropathol 2005; 109: 457–466.
107. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000; 1: 120–129.
108. Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium 2010; 47: 122–129.
109. Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE et al. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci USA 2010; 107: 17362–17367.
110. Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007; 317: 369–372.